Peptide receptor radionuclide therapy for metastatic paragangliomas

File Description SizeFormat 
Lutetium_Paraganglioma_paper_ RS.docAccepted version126 kBMicrosoft WordView/Open
Title: Peptide receptor radionuclide therapy for metastatic paragangliomas
Authors: Pinato, DJ
Black, JRM
Ramaswami, R
Tan, TM
Adjogatse, D
Sharma, R
Item Type: Journal Article
Abstract: There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce. We report safety and efficacy outcomes from a case series of five patients with advanced mPGLs treated with 177Lu-DOTATATE PRRT. The mean age of our cohort was 34 years (range 16–47); 4 patients were male with bone disease being the most prevalent metastatic site. PRRT scheme varied between 1 and 4 cycles, with premature cessation due to suspected pneumonitis in one case and disease progression in another. Three patients with previously documented progressive disease achieved stabilization following treatment; one had partial response and one was treatment refractory. Median progression-free survival was 17 months (range 0–78 months). 177-Lu-DOTATATE is an effective therapy in mPGLs in this molecularly defined patient cohort, warranting further investigation in larger studies including hereditary and sporadic mPGL.
Issue Date: 1-May-2016
Date of Acceptance: 27-Jan-2016
URI: http://hdl.handle.net/10044/1/41469
DOI: https://dx.doi.org/10.1007/s12032-016-0737-9
ISSN: 1559-131X
Publisher: Springer
Journal / Book Title: Medical Oncology
Volume: 33
Issue: 5
Copyright Statement: The final publication is available at Springer via https://dx.doi.org/10.1007/s12032-016-0737-9
Sponsor/Funder: Medical Research Council (MRC)
Funder's Grant Number: MR/N020782/1
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Malignant paraganglioma
Management
Peptide receptor radionuclide therapy
Survival
MALIGNANT PHEOCHROMOCYTOMAS
LU-177-DOTA(0),TYR(3) OCTREOTATE
NEUROENDOCRINE TUMORS
DIAGNOSIS
MANAGEMENT
SURVIVAL
Oncology & Carcinogenesis
Publication Status: Published
Article Number: 47
Appears in Collections:Division of Surgery
Division of Cancer
Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx